Peculiarities of treatment of acute myocardial infarction and diagnostic issues in patients with diabetes mellitus

1.Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101-1107.

2.Suleiman M, Hammerman H, Boulos M et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: A Prospective Study. Circulation 2005; 111: 754-760.

3.Sala J, Masiá R, González de Molina FJ et al. Short-term mortality of myocardial infarction admission patients with diabetes or hyperglycaemia during admission. J. Epidemiol Community Health 2002; 56: 707-712.

4.Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140–2144.

5.Bartnik M, Malmberg K, Norhammar A et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004; 25: 1990-1997.

6.Mooy JM, Grootenhuis PA, de Vries H et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glukose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298–305.

7.Chan KC, Chou HH, Wu DJ et al. Diabetes mellitus has an additional effect on coronary artery disease. Jpn Heart J 2004; 45: 921-927.

8. Garratt KN, Brady PA, Hassinger NL et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.

9.Ishihara M, Inoue I, Kawagoe T et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 2001; 38: 1007–1111.

10.Solomon SD, Anavekar NS, Greaves S et al for the HEART Investigators. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. J Am Coll Cardiol 2004; 43: 1511–1514.

11.Zbinden R, Zbinden S, Billinger M et al. Influence of diabetes mellitus on coronary collateral flow: an answer to an old controversy. Heart 2005; 91: 1289-1293.

12.Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47: 693-700.

13.Fox CS, Sullivan L, D’Agostino RB, Wilson PWF. The significant effect of diabetes duration on coronary heart disease mortality: The Framingham Heart Study. Diabetes Care 2004; 27: 704-708.

14. Kvan E, Reikvam A for INPHARM Study Investigators. Thrombolytic treatment in diabetic patients with acute myocardial infarction: lower rates of use than in nondiabetic patients are explained by differences in presenting ECGs. Heart 2004; 90: 1346–1347.

15.Kondo T, Kubota I, Tachibana H et al. Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Cardiovasc Res 1996; 31: 683–687.

16.Huizar JF, Gonzalez LA, Alderman J et al. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol 2003; 42: 1017-1021.

17.Murcia AM, Hennekens CH, Lamas GA et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004; 164: 2273-2279.

18.Piechowski-Jozwiak B, Maulaz A, Bogousslavsky J. Secondary prevention of stroke with antiplatelet agents in patients with diabetes mellitus. Cerebrovasc Dis 2005; 20(Suppl 1): 15-23.

19.Brown LC, Johnson JA, Majumdar SR et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004; 171: 1189-1192.

20.Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994; 343: 311–322.

21.Zairis MN, Lyras AG, Makrygiannis SS et al. Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction. Diabetes Care 2004; 27: 967-971.

22.Mak KH, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000; 35: 563-568.

23.Harjai KJ, Stone GW, Boura J Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 1041-1045.

24.Hsu LF, Mak KH, Lau KW et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis. Heart 2002; 88: 260-265.

25.Silva JA, Ramee SR, White CJ et al. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 1999;138: 446–455.

26.Angeja BG, de Lemos J, Murphy SA et al. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J 2002; 144: 649-656.

27.Prasad A, Stone GW, Stuckey TD et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005; 45: 508-514.

28.Mathew V, Gersh BJ, Williams BA et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. Circulation 2004; 109: 476-480.

29.Marfella R, Siniscalchi M, Esposito K et al. Effects of stress hyperglycemia on acute myocardial infarction: Role of inflammatory immune process in functional cardiac outcome. Diabetes Care 2003; 26: 3129-3135.

30.Malmberg K, Ryde´n L, Wedel H et al for the DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650–661.

31.Malmberg K on behalf of the Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study Group. Prospective randomized study of intensive insulin-treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512–1515.

32.Malmberg K, Ryde´n L, Wedel H et al for the DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650–661.

33.The CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. JAMA 2005; 293: 437-446.

34.Shekelle PG et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the managementof left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538.

35.Prasad A, Stone GW, Stuckey TD et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005; 45: 508-514.

36.Lincoff AM. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 2003; 107: 1556-1559.